Voxelotor (hemolytic anemia due to sickle cell disease, patients aged ≥ 12 years, monotherapy or combined with hydroxycarbamide)

Subject:

• Active Substance: Voxelotor
• Name: Oxbryta^®
• Therapeutic area: Sickle cell disease
• Pharmaceutical company: Global Blood Therapeutics Germany GmbH

Time table:

• Start: 15.05.2022
• Final decision by G-BA: 03.11.2022

Final decision:

• Hint for a non-quantifiable additional benefit